Showing 951-960 of 18562 results for "".
The Endocrine Society's 2010 Annual Meeting
https://reachmd.com/programs/conference-coverage/the-endocrine-societys-2010-annual-meeting/5743/Hear highlights from research on the management of obesity, endocrine disorders, diabetes, menopause, and thyroid cancer presented at the Endocrine Society's 92nd Annual Meeting and Expo. The meeting took place June 19 to 22, 2010, in San Diego.Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
https://reachmd.com/programs/Audioabstracts/vedolizumab-induction-and-maintenance-therapy-crohns-disease-patients-naive-or-who-have-failed-tumor/9537/Vedolizumab had increased efficacy over placebo in CD patients irrespective of TNF-α antagonist treatment history.Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
https://reachmd.com/programs/heart-matters/improving-attr-cm-diagnosis-insights-on-heart-failure-phenotypes/35756/Because current guidelines for detecting transthyretin amyloid cardiomyopathy (ATTR-CM) may miss a significant number of patients, a recent study published in the Journal of the American College of Cardiology examined heart failure phenotypes that could constitute overlooked presentations of the disPreventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
https://reachmd.com/programs/project-oncology/preventing-mgussmm-progression-to-multiple-myeloma-with-dietary-interventions/30046/A recent study found that a high-fiber, plant-based diet can delay progression from MGUS and SMM to multiple myeloma. Here are the best foods for patients.From IVIg to SCIg: Rethinking Long-Term CIDP Therapy
https://reachmd.com/programs/medical-industry-feature/from-ivig-to-scig-rethinking-long-term-cidp-therapy/33064/Immunoglobulin is initially administered intravenously (IVIg) to help patients with chronic inflammatory demyelinating polyneuropathy (CIDP) regain function and stabilize their symptoms.1,2 However, over time, issues like systemic side effects, venous access difficulties, and fluctuating Ig levels cSubcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
https://reachmd.com/programs/project-oncology/subcutaneous-isatuximab-matches-iv-in-multiple-myeloma-insights-from-iraklia/36403/The phase 3 IRAKLIA trial evaluated the subcutaneous delivery of isatuximab via an on-body injector plus pomalidomide and dexamethasone versus the standard IV regimen in patients with relapsed/refractory multiple myeloma. Results showed comparable overall response rates, steady-state trough concentrAdvances in Osteoporosis Treatment: Exploring Drug and Non-Drug Interventions
https://reachmd.com/programs/frontlines-osteoporosis/advances-in-osteoporosis-treatment-exploring-drug-and-non-drug-interventions/32344/Treatment for osteoporosis spans a variety of drug and non-drug interventions, from proper nutrition and exercise to anabolic and antiresorptive agents. In addition to understanding the importance of these therapies, it's crucial to recognize the patient's individual risks and needs and personalizeImproving CKD Patient Outcomes with SGLT2 Inhibitors
https://reachmd.com/programs/clinicians-roundtable/improving-ckd-patient-outcomes-with-sglt2-inhibitors/17943/How are SGLT2 inhibitors helping patients with CKD? Tune in.JAMA: Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies
https://reachmd.com/programs/Audioabstracts/jama-noninvasive-prenatal-testing-and-incidental-detection-occult-maternal-malignancies/7628/Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies Diana W. Bianchi, MD; Darya Chudova, PhD; Amy J. Sehnert, MD; Sucheta Bhatt, MD; Kathryn Murray, MS; Tracy L. Prosen, MD; Judy E. Garber, MD; Louise Wilkins-Haug, MD, PhD; Neeta L. Vora, MD; Stephen Warsof, MD; JamWomen In Aesthetics: Mary Gardner, DelNova, Inc
https://modernaesthetics.com/topics/skincare/women-in-aesthetics-mary-gardner-delnova-inc/35165/